These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 19485752)

  • 1. Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.
    ;
    Expert Rev Vaccines; 2009 Jun; 8(6):705-16. PubMed ID: 19485752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A global perspective on vaccine safety.
    Duclos P
    Vaccine; 2004 May; 22(15-16):2059-63. PubMed ID: 15121323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving global monitoring of vaccine safety: a quantitative analysis of adverse event reports in the WHO Adverse Reactions Database.
    Letourneau M; Wells G; Walop W; Duclos P
    Vaccine; 2008 Feb; 26(9):1185-94. PubMed ID: 18243428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety monitoring in vaccine development and immunization.
    Lee CJ; Lee LH; Lu CH; Huang YJ; Chu ML
    Acta Paediatr Taiwan; 2006; 47(1):7-13. PubMed ID: 17016963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring and assessing vaccine safety: a European perspective.
    Lopalco PL; Johansen K; Ciancio B; De Carvalho Gomes H; Kramarz P; Giesecke J
    Expert Rev Vaccines; 2010 Apr; 9(4):371-80. PubMed ID: 20370548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capacity for a global vaccine safety system: the perspective of national regulatory authorities.
    Graham JE; Borda-Rodriguez A; Huzair F; Zinck E
    Vaccine; 2012 Jul; 30(33):4953-9. PubMed ID: 22658930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine adverse events in the new millennium: is there reason for concern?
    Ward BJ
    Bull World Health Organ; 2000; 78(2):205-15. PubMed ID: 10743286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing a national system for dealing with adverse events following immunization.
    Mehta U; Milstien JB; Duclos P; Folb PI
    Bull World Health Organ; 2000; 78(2):170-7. PubMed ID: 10743281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006.
    Chang S; Ball R; Braun MM
    Vaccine; 2008 May; 26(19):2428-32. PubMed ID: 18406499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization.
    Amarasinghe A; Black S; Bonhoeffer J; Carvalho SM; Dodoo A; Eskola J; Larson H; Shin S; Olsson S; Balakrishnan MR; Bellah A; Lambach P; Maure C; Wood D; Zuber P; Akanmori B; Bravo P; Pombo M; Langar H; Pfeifer D; Guichard S; Diorditsa S; Hossain MS; Sato Y
    Vaccine; 2013 Apr; 31 Suppl 2():B108-14. PubMed ID: 23598471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
    Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
    Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination vaccines: postlicensure safety evaluation.
    Chen RT; Pool V; Takahashi H; Weniger BG; Patel B
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S327-33. PubMed ID: 11709768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The complicated task of monitoring vaccine safety.
    Ellenberg SS; Chen RT
    Public Health Rep; 1997; 112(1):10-20; discussion 21. PubMed ID: 9018282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
    Patel MM; Parashar UD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety considerations for new vaccine development.
    Ellenberg SS
    Pharmacoepidemiol Drug Saf; 2001; 10(5):411-5. PubMed ID: 11802587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of vaccine surveillance data in the evaluation of safety of vaccines.
    Postila V; Kilpi T
    Vaccine; 2004 May; 22(15-16):2076-9. PubMed ID: 15121327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods of ensuring vaccine safety.
    Ball R
    Expert Rev Vaccines; 2002 Aug; 1(2):161-8. PubMed ID: 12901555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine safety: current systems and recent findings.
    Wharton M
    Curr Opin Pediatr; 2010 Feb; 22(1):88-93. PubMed ID: 19952750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Essential to monitor vaccine safety].
    Heijbel H
    Lakartidningen; 2001 Sep; 98(36):3777-8. PubMed ID: 11586806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.